Evidence map›Paper›PMID 32666718›Full record

ArticleMolecular genetics & genomic medicine2020

Development of an immune-related prognostic model for pediatric acute lymphoblastic leukemia patients.

Xi Quan, Nan Zhang, Ying Chen, Hanqing Zeng, Jianchuan Deng

Abstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xi QuanDepartment of Hematology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. China.ORCID 0000-0003-1829-2649
Nan ZhangDepartment of Hematology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. China.
Ying ChenDepartment of Hematology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. China.
Hanqing ZengDepartment of Hematology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. China.
Jianchuan DengDepartment of Hematology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute lymphoblastic leukemia (ALL) is the most common hematological malignancy in pediatrics, and immune-related genes (IRGs) play crucial role in its development. Our study aimed to identify prognostic immune biomarkers of pediatric ALL and construct a risk assessment model.

methodsPediatric ALL patients' gene expression data were downloaded from Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database. We screened differentially expressed IRGs (DEIRGs) between the relapse and non-relapse groups. Cox regression analysis was used to identify optimal prognostic genes, then, a risk model was constructed, and its accuracy was verified in different cohorts.

resultsWe screened 130 DEIRGs from 251 pediatric ALL samples. The top three pathways that DEIRGs may influence tumor progression are NABA matrisome-associated, chemotaxis, and antimicrobial humoral response. A set of 84 prognostic DEIRGs was identified by using univariate Cox analysis. Then, Lasso regression and multivariate Cox regression analysis screened four optimal genes (PRDX2, S100A10, RORB, and SDC1), which were used to construct the prognostic risk model. The risk score was calculated and the survival analysis results showed that high-risk score was associated with poor overall survival (OS) (p = 3.195 × 10

conclusionsOur prognostic risk model can effectively divide pediatric ALL patients into high-risk and low-risk groups, which may help predict clinical prognosis and optimize individualized treatment.

Indexed as

TranscriptomeAnnexin A2Biomarkers, TumorFemaleHumansInfantMaleNuclear Receptor Subfamily 1, Group F, Member 2PeroxiredoxinsPrecursor Cell Lymphoblastic Leukemia-LymphomaS100 Calcium Binding Protein A10S100 ProteinsSyndecan-1Annexin A2Biomarkers, TumorNuclear Receptor Subfamily 1, Group F, Member 2PeroxiredoxinsPRDX2 protein, humanRORB protein, humanS100 Calcium Binding Protein A10S100 ProteinsSDC1 protein, humanSyndecan-1immune-related genespediatric acute lymphoblastic leukemiaprognosissurvival analysis

Identifiers

PMID32666718
PMCPMC7507390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.